Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.
About
ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates.
Tags
Total Employees
36
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
56Traction
55Team
30Visibility
40Profile
75Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ONCOMATRYX do?
ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates.
How much funding has ONCOMATRYX raised?
ONCOMATRYX has raised a total of $107M in funding. The most recent round on record is Funding Round.
Where is ONCOMATRYX headquartered?
ONCOMATRYX is headquartered in Derio, Spain.
When was ONCOMATRYX founded?
ONCOMATRYX was founded in 2009.
What industry does ONCOMATRYX operate in?
ONCOMATRYX operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.
How many employees does ONCOMATRYX have?
ONCOMATRYX has approximately 36 people on record.